Searched for
ZYDUS LIFE SCIENCES
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- From Tata to tech giants, Indian companies tighten grip on UK economyIndian businesses are significantly expanding their UK presence, with company numbers soaring by nearly 60% and combined revenues exceeding...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Zydus eyes major stake in French medtech Amplitude for Rs 2,446 croreIndia's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global ...
- Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costsThe company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended ...
- MNC pharma body OPPI appoints Anil Matai as new director generalThe Organisation of Pharmaceutical Producers of India (OPPI) has appointed Anil Matai as its director general. Matai has extensive experien...
- Sun Pharma, Lupin among 9 BSE Healthcare stocks that hit new 52-week highs on ThursdayThe healthcare sector's impressive performance in the stock market highlights these companies' commitment to innovation, research, and deli...
- Stocks in news: Nazara Tech, ZEE, Anupam Rasayan, Tata Chemicals, Kotak BankShares of Tata Chemicals and Canara Bank will be in focus today as the companies will go ex-dividend today. Tata Chemicals has also followe...
- Zydus gets DCGI nod for drug to treat anaemia associated with chronic kidney diseaseZydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a f...
- Reliance Life gets regulatory nod for trials of 2-dose vaccineThe drug regulatory authority on Thursday approved Reliance Life Sciences, part of India's largest private sector enterprise-application, s...
- Bayer's Aflibercept injection gets DCGI nod for Diabetic Macular Edema indicationDiabetic Macular Edema occurs when high blood sugar levels damage capillaries that leak fluid into the retina, resulting in swelling and bl...
- Zydus Cadila launches India's cheapest remdesivir version at Rs 2,800 per 100 mg vialZydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Li...
- Pharma, life sciences companies scale up hiring as production increasesAccording to Xpheno, a staffing firm catering to the pharma sector, as many as 30,000 vacancies exist across the pharma space, in areas of ...
- More companies in talks for Remdesivir licenceThis week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received ...
- Bayer CropScience appoints Pankaj Patel as chairmanBayer CropScience informed that the board appointed Pankaj Patel as an additional non-executive director of the company with effect from Ju...
- Zydus Cadila launches copy of Roche’s breast cancer drug HerceptinZydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...
- Zydus Cadila in talks to buy Strides Arcolab' Rs 70-crore India generic businessZydus Cadila is in early stages of talks to acquire Bangalore-based Strides Arcolab's Rs 70-crore domestic generic business.
- Sharekhan recommends ‘buy’ on Cadila HealthcareSharekhan has recommended ‘buy’ on Cadila Healthcare with a target price of Rs.372. At the current market price of Rs272, the stock is avai...
Load More
